Bioaccelerate Holdings Inc. Announces Sponsorship of Milken Institute Global Conference
February 16 2005 - 8:00AM
PR Newswire (US)
Bioaccelerate Holdings Inc. Announces Sponsorship of Milken
Institute Global Conference NEW YORK, Feb. 16
/PRNewswire-FirstCall/ -- Bioaccelerate Holdings Inc. (BACL.OB), a
company that acquires and invests in the development of
pharmaceutical compounds, announced today its sponsorship of the
annual Milken Institute Global Conference, taking place April
18-April 20, 2005 at the Beverly Hilton Hotel in Los Angeles, CA.
The conference draws together more than 2,000 senior decision
makers from industry, government, financial institutions, and
philanthropy from over 50 countries to discuss and debate ideas
about how to solve some of the world's most pressing challenges.
"Bioaccelerate is delighted to be a major sponsor of this important
annual event for the second year in a row," stated Frank Armstrong,
M.D., Chief Operating Officer of Bioaccelerate. "Among the topics
to be discussed at this year's conference will be university-based
biotechnology research, development and commercialization. In a
panel discussion to be led by Bioaccelerate, prominent experts from
academia and the pharmaceutical industry will explore ways to help
facilitate more efficient technology transfer so that promising new
medicines can be brought to market more quickly and cost
effectively." This year's conference, "Building a Prosperous
Future," will examine such issues as biotechnology and the promise
of medical breakthroughs; the global investment climate; and the
latest economic developments in Europe, Asia, Russia, Latin America
and the U.S. Among confirmed speakers at the conference are former
Vice President Al Gore; Rupert Murdoch, Chairman and CEO, News
Corporation; Terry Semel, Chairman and CEO, Yahoo!; Charlene
Barshefsky, former U.S. Trade Representative; Mel Karmazin, CEO,
SIRIUS Satellite Radio; Steve Forbes, President and CEO, Forbes;
William Haseltine, former CEO, Human Genome Sciences; Douglas
Holtz-Eakin, Director, Congressional Budget Office; Jonathan
Miller, Chairman and CEO, AOL; Mike Milken, Chairman of FasterCures
and the Milken Institute; Steve Wynn, President and CEO, Wynn
Resorts; Sam Zell, Chairman, Equity Group Investments; and more
than 200 others. For complete information about the 2005 Global
Conference, go to: http://www.milkeninstitute.org/gc2005. About
Bioaccelerate Holdings Inc. Bioaccelerate Holdings Inc. is a
pharmaceutical development organization that seeks to acquire,
develop and commercialize novel pharmaceutical compounds in an
efficient, cost-effective way for the benefit patients and its
shareholders. Bioaccelerate uses its broad network of academic,
industry and capital market relationships to expedite drug
development and raise capital to create and fund its subsidiary
companies, which are organized by vertical portfolios in five
therapeutic areas: oncology, specialty pharmaceuticals, central
nervous system disorders (CNS), cardiovascular disease and
anti-infectives. Bioaccelerate conducts its business directly and
through its subsidiaries. The company holds majority equity
interests in ten biopharmaceutical companies (three of which are
public) and holds minority interests in four biopharmaceutical
companies (two of which are public). The company also holds a
minority equity interest in a public nanotechnology company.
Bioaccelerate's strategy relies on its development network for
research, clinical development and project management to guide
early-stage compounds from the discovery process through to Phase
II/III development where incremental value can be created.
Bioaccelerate Holdings is quoted on the Over-The-Counter Bulletin
Board under the symbol "BACL.OB." For more information on
Bioaccelerate, visit the company's website at
http://www.bioaccelerate.com/. Bioaccelerate Safe Harbor Statement
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: risks associated with
pre-clinical and clinical developments in the biopharmaceutical
industry in general and in Bioaccelerate's compounds under
development in particular; the potential failure of Bioaccelerate's
compounds under development to prove safe and effective for
treatment of disease; uncertainties inherent in the early stage of
Bioaccelerate's compounds under development; failure to
successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioaccelerate's
business, structure or projections; the development of competing
products; uncertainties related to Bioaccelerate's dependence on
third parties and partners. Bioaccelerate disclaims any obligation
to update these forward-looking statements. About the Milken
Institute The Milken Institute is a nonprofit, independent economic
think tank whose mission is to improve the lives and economic
conditions of diverse populations around the world by helping
business and public policy leaders identify and implement
innovative ideas for creating broad-based prosperity. It is based
in Santa Monica, CA. (http://www.milkeninstitute.org/) Contact:
Bioaccelerate Holdings Inc. Christopher O'Toole Senior Vice
President 212-897-6849 Matthew Haines (Investors) Vice President
Noonan Russo 212-845-4235 Emily Poe (Media) Vice President Noonan
Russo 212-845-4266 DATASOURCE: Bioaccelerate Holdings Inc. CONTACT:
Christopher O'Toole, Senior Vice President of Bioaccelerate
Holdings Inc., +1-212-897-6849; or Matthew Haines (Investors), Vice
President, +1-212-845-4235, or Emily Poe (Media), Vice President,
+1-212-845-4266, both of Noonan Russo, for Bioaccelerate Holdings
Inc. Web site: http://www.bioaccelerate.com/
http://www.milkeninstitute.org/
http://www.milkeninstitute.org/gc2005
Copyright